Ceribell, Inc.
CBLL · XNASCIK 1861107fmd_1RHT43RG1GY0GGGNTQYSVCVQB4Manufacturing · Electromedical & Electrotherapeutic ApparatusTemplate: Standard
Coverage: Jan 01, 2023 to Sep 30, 2026, 15 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total revenues | 45 | 65 | 89 |
| Cost of revenue | 7 | 9 | 11 |
| Gross profit | 38 | 57 | 78 |
| Research and development | 9 | 14 | 19 |
| Selling, general and administrative | 59 | 83 | 118 |
| Total operating expenses | 68 | 96 | 137 |
| Operating income | (30) | (40) | (58) |
| Interest expense | 2 | 2 | 2 |
| Other non-operating income (expense) | 3 | 3 | 7 |
| Income before taxes | (29) | (40) | (53) |
| Income tax expense | 0 | 0 | 0 |
| Net income from continuing operations | (29) | (40) | (53) |
| Net income | (29) | (40) | (53) |